A KRAS-variant is a Biomarker of Poor Outcome, Platinum Chemotherapy Resistance and a Potential Target for Therapy in Ovarian Cancer
暂无分享,去创建一个
F. Slack | J. Weidhaas | D. Katsaros | D. Zelterman | S. Neuhausen | E. Ratner | Sunitha Nallur | Roman-Ulrich Muller | Herbert Yu | P. Schwartz | T. Rutherford | J. Weitzel | S. Bellone | A. Santin | S. Pecorelli | R. Lindner | M. Cristea | L. Steele | S. Sand | Lingeng Lu | Marta Boeke | Yanhong Deng | A. Ravaggi | E. Bignotti | F. Keane | X. Yao | T. Paranjape | R. Tassi | M. Glasgow | Xiaopan Yao